INTRODUCTION {#s1}
============

MicroRNAs (miRNAs) are a group of short noncoding RNAs of about 22 nucleotides which are involved in diverse physiological and developmental processes by controlling the gene expression of target mRNAs \[[@R1], [@R2]\]. Accumulating evidence has shown that miRNAs regulate the expression of roughly 10--30% of the all human genes through post-transcriptional mechanisms \[[@R3]\], contributing to excessive physiologic and pathologic conditions, including cell differentiation, apoptosis, development, and deregulation of these processes play critical roles in carcinogenesis \[[@R4]\].

Single nucleotide polymorphisms (SNPs) represent the most common genetic variation in human genome. SNPs in miRNA genes are regarded to affect function by three ways: first, through the transcription of the primary transcript; second, through pri-miRNA and pre-miRNA processing; and third, through effects on miRNA-miRNA interactions \[[@R5]\]. Recently, several studies have demonstrated that some SNPs present in the miRNA genes \[[@R6], [@R7]\], which can alter miRNA expression and/or maturation and be associated with the development and progression of cancer \[[@R8]\]. Thus, SNPs in miRNAs may influence susceptibility to malignant tumors. The miR-149 T \> C (rs2292832) and miR-27a A \> G (rs895819) were studied in diverse cancers. Research results about two sites were inconsistent \[[@R9], [@R10]\], this discrepancy maybe partially attributed to the heterogeneity of the cancer subtype, small sample size, and ethnicity of the patients.

To further determine whether there is an association of the rs2292832 and rs895819 in the miRNA genes with the risk for developing cancer, a comprehensive review and analysis of published data from different studies is needed. In this study, we performed a meta-analysis on all eligible case-control studies to drive a more powerful estimation of the association of rs2292832 and rs895819 SNP with cancer risks.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

The search process and the final selection of relevant studies are shown in Figure [1](#F1){ref-type="fig"}, A comprehensive literature search yielded 348 potentially relevant published articles. After further identification and screening individual study, 43 articles (49 studies) \[[@R11]--[@R53]\] underwent full-text assessment, and 6 articles (10 studies, not including one site according to HWE) \[[@R14], [@R17], [@R19], [@R20], [@R35], [@R42]\] were excluded due to inconsistently with HWE. Finally, 37 articles (40 studies) \[[@R11]--[@R13], [@R15], [@R16], [@R18], [@R21]--[@R34], [@R36]--[@R41], [@R43]--[@R53]\] were conducted in quantitative synthesis.

![Flow chart of literature search and study selection](oncotarget-07-22368-g001){#F1}

Characteristics of included studies are presented in Table [1](#T1){ref-type="table"}. A total of 39 eligible studies met the prespecified inclusion criteria, in which two articles \[[@R24], [@R52]\] included two tumor types respectively, and one article included \[[@R23]\] rs2292832 and rs895819. As for rs2292832, involving 9,994 cases and 10,757 controls were ultimately analyzed from 21 studies (20 articles) \[[@R11]--[@R13], [@R15], [@R16], [@R18], [@R21]--[@R34]\], and 19 studies (17 articles) \[[@R23], [@R36]--[@R41], [@R43]--[@R53]\] involving 7,800 cases and 9,060 controls for rs895819.

###### Main characteristics of included studies

  First author                  Year   Ethnicity   Cancer type         Source of control   Genotyping   Match[^a^](#tfn_001){ref-type="table-fn"}   Sample size   *P*~HWE~   Quality control   
  ----------------------------- ------ ----------- ------------------- ------------------- ------------ ------------------------------------------- ------------- ---------- ----------------- ----
  He BS \[[@R11]\]              2015   Asian       Breast cancer       Population          MassARRAY    Y                                           450/450       0.13                         Y
  Du ML \[[@R12]\]              2014   Asian       Renal cell cancer   Population          TaqMan       Y                                           355/362       0.46                         Y
  Dikeakos P \[[@R13]\]         2014   Caucasian   Gastric cancer      Hospital            PCR-RFLP     Y                                           163/480       0.45                         Y
  Pu JY \[[@R14]\]              2014   Asian       Gastric cancer      Hospital            PCR-RFLP     N                                           220/530       \< 0.01                      Y
  Wei WJ \[[@R15]\]             2014   Asian       PTC                 Population          MassARRAY    Y                                           838/1006      0.73                         Y
  Wang R \[[@R16]\]             2014   Asian       HCC                 Population          MassARRAY    N                                           944/984       0.86                         N
  Wu RR \[[@R17]\]              2014   Asian       Colorectal Cancer   Hospital            ASA          N                                           175/300       \< 0.01    0.02              Y
  Huang GL \[[@R18]\]           2013   Asian       NPC                 Population          PCR-RFLP     N                                           158/242       0.72                         Y
  Chu YH \[[@R19]\]             2013   Asian       HCC                 Population          PCR-RFLP     N                                           188/337       \< 0.01                      Y
  Lv M \[[@R20]\]               2013   Asian       Colorectal cancer   Population          PCR-RFLP     N                                           353/540       \< 0.01                      Y
  Song XC \[[@R21]\]            2013   Caucasian   OSCC                Population          PCR-RFLP     Y                                           325/335       0.99                         Y
  Tu HF \[[@R22]\]              2012   Asian       HNSCC               Hospital            PCR-RFLP     N                                           122/273       0.27                         NA
  Zhang M \[[@R23]\]            2012   Asian       Breast Cancer       Population          PCR-RFLP     Y                                           252/248       0.21       0.12              Y
  Zhang MW(C) \[[@R24]\]        2012   Asian       Colorectal Cancer   Population          PCR-RFLP     Y                                           443/435       0.43                         Y
  Zhang MW(G) \[[@R24]\]        2012   Asian       Gastric Cancer      Population          PCR-RFLP     Y                                           274/269       0.70                         Y
  Min KT \[[@R25]\]             2012   Asian       Colorectal Cancer   Population          PCR-RFLP     N                                           446/502       0.62                         Y
  Ahn DH \[[@R26]\]             2012   Asian       Gastric Cancer      Population          PCR-RFLP     N                                           461/447       0.98                         Y
  Kim WH \[[@R27]\]             2012   Asian       HCC                 Population          PCR-RFLP     N                                           159/201       0.34                         Y
  Vinci S \[[@R28]\]            2013   Caucasian   Colorectal Cancer   Population          HRM          Y                                           160/178       0.91                         Y
  Vinci S \[[@R29]\]            2011   Caucasian   Lung Cancer         Population          HRM          Y                                           101/129       0.97                         Y
  Li PY \[[@R30]\]              2011   Asian       NPC                 Hospital            TaqMan       Y                                           791/1016      0.49                         NA
  Zhang MW \[[@R31]\]           2011   Asian       Lung Cancer         Population          PCR-RFLP     Y                                           232/231       0.12                         Y
  Liu ZS \[[@R32]\]             2010   Caucasian   HNSSC               Population          PCR-RFLP     Y                                           1109/1130     0.72                         Y
  Tian T \[[@R33]\]             2009   Asian       Lung Cancer         Population          PCR-RFLP     Y                                           1058/1035     0.86                         Y
  Wang ZW \[[@R34]\]            2009   Asian       Breast Cancer       Population          PCR-RFLP     Y                                           1009/1093     0.16                         Y
  Ma JY \[[@R35]\]              2015   Asian       NSCC                Population          TaqMan       Y                                           542/557                  0.02              Y
  Qi P \[[@R36]\]               2015   Asian       Breast cancer       Population          TaqMan       Y                                           321/290                  0.69              N
  Yin ZH \[[@R37]\]             2015   Asian       Lung Cancer         Hospital            TaqMan       Y                                           258/310                  0.70              Y
  Cao Y \[[@R38]\]              2014   Asian       Colorectal cancer   Population          PCR-RFLP     Y                                           254/238                  0.09              Y
  Kupcinskas J (C) \[[@R39]\]   2014   Caucasian   Colorectal cancer   Hospital            TaqMan       N                                           193/428                  0.24              Y
  Kupcinskas J (G) \[[@R40]\]   2014   Caucasian   Gastric cancer      Hospital            TaqMan       N                                           363/351                  0.15              Y
  Song B \[[@R41]\]             2014   Asian       Gastric cancer      Population          TaqMan       Y                                           278/278                  0.11              Y
  Wang ZQ \[[@R42]\]            2014   Asian       Colorectal cancer   Hospital            TaqMan       N                                           205/455                  \< 0.01           Y
  Zhang JJ \[[@R43]\]           2014   Asian       ESCC                Population          SNaPshot     Y                                           1109/1275                0.23              Y
  Zhang N \[[@R44]\]            2013   Asian       Breast cancer       Population          TaqMan       Y                                           264/255                  0.45              N
  Catucci I \[[@R45]\]          2012   Caucasian   Breast Cancer       Hospital            TaqMan       Y                                           1,025/1,593              0.051             Y
  Hezova R \[[@R46]\]           2012   Caucasian   Colorectal Cancer   Population          TaqMan       Y                                           197/202                  0.87              NA
  Shi DN \[[@R47]\]             2012   Asian       Renal Cell Cance    Population          TaqMan       Y                                           594/600                  0.37              Y
  Zhang MW \[[@R48]\]           2012   Asian       Colorectal Cancer   Population          PCR-RFLP     Y                                           463/468                  0.35              Y
  Zhou Y \[[@R49]\]             2012   Asian       Gastric cancer      Hospital            MassARRAY    Y                                           311/425                  0.94              Y
  Zhang P \[[@R50]\]            2011   Asian       Breast Cancer       Population          MassARRAY    Y                                           384/192       \< 0.01    0.61              Y
  Sun QM \[[@R51]\]             2010   Asian       Gastric cancer      Hospital            PCR-RFLP     Y                                           304/304                  0.053             Y
  Kontorovich T(B) \[[@R57]\]   2010   Caucasian   Breast cancer       Population          iPLEX        N                                           86/106        \< 0.01    0.37              Y
  Kontorovich T(O) \[[@R52]\]   2010   Caucasian   Ovarian cancer      Population          iPLEX        N                                           34/106        \< 0.01    0.37              Y
  Yang RX \[[@R53]\]            2010   Caucasian   Breast cancer       Population          TaqMan       Y                                           1189/1416                0.14              Y

Match, controls and cases were matched on age and gender; ASA, allele-specific amplification; OSCC, oral squamous cell carcinoma; HNSCC, head and neck squamous cell carcinoma; HCC, hepatic cell carcinoma; NPC, Nasopharyngeal Carcinoma; NSCC, Non small cell Lung cancer; PTC, Papillary Thyroid Cancer.

All studies were case-control studies, including 40 studies on 10 breast cancer, 7 gastric cancer, 7 colorectal cancer, 4 lung cancer, and 12 on other cancer types. There were 28 studies of Asian descendent, 11 of Caucasian descendent. A classic PCR-RFLP assay was used in 17 out of 40 studies, the other molecular genotyping methods, such as Taqman, MassARRAY, and HRM, were used in other studies. 32 studies were randomly repeated a portion of samples as quality control while genotyping.

Quality assessment {#s2_2}
------------------

According to the NOS for quality of case-control, the study-specific quality scores are summarized in Table [2](#T2){ref-type="table"}. A star system of the NOS (range, 0--9 scores) has been developed for the evaluation, and the quality scores ranged from 4 to 8. The average scores of case-control studies were 6.49.

###### Quality assessment of included studies based on the newcastle--ottawa scale

  Study                         Selection (score)               Comparability (score)   Exposure (score)           Total score[^b^](#tfn_003){ref-type="table-fn"}
  ----------------------------- ------------------- --- --- --- ----------------------- ------------------ --- --- -------------------------------------------------
  He BS \[[@R11]\]              1                   1   1   1   2                       0                  1   0   **7**
  Du ML \[[@R12]\]              1                   1   1   1   2                       0                  1   0   **7**
  Dikeakos P \[[@R13]\]         1                   1   0   1   2                       0                  1   1   **7**
  Wei WJ \[[@R15]\]             1                   1   1   1   2                       0                  1   0   **7**
  Wang R \[[@R16]\]             1                   1   0   1   1                       0                  1   0   **5**
  Huang GL \[[@R18]\]           1                   1   1   1   2                       0                  1   0   **7**
  Song XC \[[@R21]\]            1                   1   1   1   2                       0                  1   1   **8**
  Tu HF \[[@R22]\]              1                   1   0   1   2                       0                  1   0   **6**
  Zhang M \[[@R23]\]            1                   1   1   1   2                       0                  1   0   **7**
  Zhang MW \[[@R24]\]           1                   1   1   1   2                       0                  1   0   **7**
  Min KT \[[@R25]\]             1                   1   1   1   2                       0                  1   0   **7**
  Aho DH \[[@R26]\]             1                   1   1   1   2                       0                  1   1   **8**
  Kim WH \[[@R27]\]             1                   1   1   1   2                       0                  1   0   **7**
  Vinci S \[[@R28]\]            1                   1   1   1   1                       0                  1   0   **6**
  Vinci S \[[@R29]\]            1                   1   0   1   2                       0                  1   0   **7**
  Li PY \[[@R30]\]              1                   1   0   1   2                       0                  1   0   **6**
  Zhang MW \[[@R31]\]           1                   1   1   1   2                       0                  1   0   **7**
  Liu ZS \[[@R32]\]             1                   1   1   1   2                       0                  1   1   **8**
  Tian T \[[@R33]\]             1                   1   1   1   2                       0                  1   0   **7**
  Wang ZW \[[@R34]\]            1                   1   1   1   1                       0                  1   0   **6**
  Qi P \[[@R36]\]               1                   1   1   1   2                       0                  1   0   **7**
  Yin ZH \[[@R37]\]             1                   1   0   1   2                       0                  1   0   **6**
  Cao Y \[[@R38]\]              1                   1   1   1   2                       0                  1   0   **7**
  Kupcinskas J (C) \[[@R39]\]   1                   1   0   1   0                       0                  1   0   **4**
  Kupcinskas J (G) \[[@R40]\]   1                   1   0   1   2                       0                  1   0   **6**
  Song B \[[@R41]\]             1                   1   1   1   2                       0                  1   0   **7**
  Zhang JJ \[[@R42]\]           1                   1   1   1   2                       0                  1   0   **7**
  Zhang N \[[@R43]\]            1                   1   1   1   2                       0                  1   0   **7**
  Catucci I \[[@R44]\]          1                   1   0   1   1                       0                  1   0   **5**
  Hezova R \[[@R45]\]           1                   1   1   1   1                       0                  1   0   **6**
  Shi DN \[[@R46]\]             1                   1   1   1   2                       0                  1   0   **7**
  Zhang MW \[[@R47]\]           1                   1   1   1   0                       0                  1   0   **5**
  Zhou Y \[[@R49]\]             1                   1   0   1   1                       0                  1   0   **5**
  Zhang P \[[@R50]\]            1                   1   1   1   1                       0                  1   0   **6**
  Sun QM \[[@R51]\]             1                   1   0   1   2                       0                  1   0   **6**
  Kontorovich T \[[@R52]\]      1                   1   1   1   0                       0                  1   0   **5**
  Yang RX \[[@R53]\]            1                   1   1   1   2                       0                  1   0   **7**

When there was no statistical significance in the response rate between case and control groups by using a chi-squared test (*P* \> 0.05), one point was awarded.

Total score was calculated by adding up the points awarded in each item.

Quantitative data synthesis {#s2_3}
---------------------------

For all of control subjects included in this study, the frequencies of risk C allele in rs2292832 for Caucasians and Asians were 33.66% (Mean ± SEM, 33.66% ± 2.18%) and 50.20% (Mean ± SEM, 50.20% ± 12.34%) (Figure [2A](#F2){ref-type="fig"}). The frequencies of risk G allele in rs895819 for Caucasians and Asians were 30.78% (Mean ± SEM, 30.78% ± 2.04%) and 29.63% (Mean ± SEM, 29.63% ± 1.45%) (Figure [2B](#F2){ref-type="fig"}). The frequencies of risk C allele in rs2292832 varied greatly among different control populations (*P* = 0.00).

![(A) frequencies of C allele in rs2292832 among controls stratified by ethnicity (B) frequencies of G allele in rs895819 among controls stratified by ethnicity](oncotarget-07-22368-g002){#F2}

For the rs2292832 polymorphism, no significant risk association was observed in the overall pooled analysis (Table [3](#T3){ref-type="table"}, Figure [3](#F3){ref-type="fig"}). When grouped by the cancer types, significant associations were found in breast cancer (CT + CC vs TT: OR = 0.83, 95% CI: 0.70--0.98, *P =* 0.03; CC vs CT + TT: OR = 0.80, 95% CI: 0.68--0.93, *P* = 0.00) (Table [4](#T4){ref-type="table"}).

###### Main results of pooled ORs of the rs2292832 and rs895819 polymorphisms on cancer risk in the meta-analysis

  comparisons     Cases        Controls     Heterogeneity test   Summary OR (*95% CI*)   Hypothesis test   Studies                          
  --------------- ------------ ------------ -------------------- ----------------------- ----------------- ------------------ ------ ------ ----
  rs2292832                                                                                                                                 
  C vs T          7995/19596   8591/20464   20.34                0.09                    36                0.93 (0.84,1.06)   0.52   0.13   20
  CT vs TT        4129/7759    4611/8511    23.96                0.20                    21                0.95 (0.89,1.01)   1.58   0.11   20
  CC vs TT        1910/5536    2020/5820    21.82                0.06                    40                0.97 (0.82,1.14)   0.40   0.69   20
  CT + CC vs TT   6039/9669    6650/10550   32.71                0.01                    44                0.93 (0.85,1.01)   0.68   0.09   20
  CC vs CT + TT   2068/9994    2182/10757   47.55                \< 0.01                 51                1.00 (0.88,1.14)   0.08   0.94   21
  rs895819                                                                                                                                  
  G vs A          4725/15804   5412/17610   43.16                \< 0.01                 58                0.99 (0.91,1.17)   0.09   0.93   19
  AG vs AA        3179/7062    3692/7976    30.95                0.03                    45                0.99 (0.88,1.12)   0.19   0.85   19
  GG vs AA        798/4681     873/5217     27.45                0.04                    42                1.07 (0.91,1.26)   0.80   0.42   19
  AG + GG vs AA   3987800      4464/9060    42.79                \< 0.01                 77                1.13 (0.97,1.31)   1.55   0.12   19
  GG vs AG + AA   798/7770     873/8911     37.20                0.01                    52                1.06 (0.90,1.25)   0.69   0.49   19

![Forest plot of cancer risk associated with rs2292832 for the recessive model (CT vs TT)\
The squares and horizontal lines correspond to the study-specific OR and 95% CI. The area of the squares reflects the study specific weight. The diamond represents the pooled OR and 95% CI.](oncotarget-07-22368-g003){#F3}

###### Stratified analyses of rs2292832 polymorphism on cancer risk

  Comparisons                    Heterogeneity test   Summary OR (*95% CI*)   Hypothesis test   Studies                          
  ------------------------------ -------------------- ----------------------- ----------------- ------------------ ------ ------ ----
  Ethnic Asian                                                                                                                   
  C vs T                         51.04                \< 0.01                 49                0.90 (0.81,1.01)   1.86   0.06   16
  CT vs TT                       18.78                0.22                    20                0.94 (0.88,1.01)   1.70   0.09   16
  CC vs TT                       33.84                0.01                    41                0.93 (0.78,1.11)   0.79   0.43   16
  CT + CC vs TT                  3.93                 0.02                    44                0.94 (0.87,1.03)   1.31   0.19   16
  CC vs CT + TT                  32.41                0.02                    38                1.00 (0.88,1.14)   0.08   0.94   16
  Caucasian                                                                                                                      
  C vs T                         2.55                 0.28                    22                1.06 (0.84,1.33)   0.47   0.63   4
  CT vs TT                       4.73                 0.19                    37                1.02 (0.82,1.25)   0.14   0.89   4
  CC vs TT                       10.45                0.02                    61                1.16 (0.67,2.01)   0.54   0.59   4
  CT + CC vs TT                  6.09                 0.11                    11                1.08 (0.88,1.31)   0.72   0.47   4
  CC vs CT + TT                  8.12                 0.09                    51                1.10 (0.86,1.41)   0.79   0.43   5
  Cancer types                                                                                                                   
  Colorectal Cancer                                                                                                              
  C vs T                         0.79                 0.67                    0                 0.97 (0.85,1.10)   0.48   0.63   3
  CT vs TT                       0.02                 0.99                    0                 0.85 (0.71,1.02)   1.72   0.09   3
  CC vs TT                       1.02                 0.60                    0                 0.94 (0.71,1.25)   0.42   0.68   3
  CT + CC vs TT                  1.12                 0.57                    0                 0.87 (0.67,1.15)   0.97   0.33   3
  CC vs CT + TT                  0.32                 0.96                    0                 1.13 (0.97,1.33)   1.56   0.12   3
  Lung Cancer                                                                                                                    
  C vs T                         3.65                 0.16                    45                0.97 (0.86,1.08)   0.63   0.53   3
  CT vs TT                       1.99                 0.37                    0                 0.86 (0.67,1.11)   1.14   0.25   3
  CC vs TT                       4.43                 0.11                    55                0.93 (0.73,1.20)   0.53   0.60   3
  CT + CC vs TT                  1.62                 0.44                    0                 1.03 (0.83,1.28)   0.25   0.80   3
  CC vs CT + TT                  3.28                 0.19                    39                0.96 (0.83,1.12)   0.48   0.63   3
  Breast Cancer                                                                                                                  
  C vs T                         13.72                \< 0.01                 55                0.82 (0.61,1.10)   1.31   0.19   3
  CT vs TT                       2.19                 0.33                    9                 0.86 (0.72,1.03)   1.64   0.10   3
  CC vs TT                       5.81                 0.55                    46                0.82 (0.65,1.03)   1.73   0.08   3
  CT + CC vs TT                  2.72                 0.26                    26                0.83 (0.70,0.98)   2.18   0.03   3
  CC vs CT + TT                  2.82                 0.24                    29                0.80 (0.68,0.93)   2.81   0.00   3
  Other cancers                                                                                                                  
  C vs T                         13.42                0.06                    45                0.91 (0.78,1.05)   1.29   0.20   11
  CT vs TT                       19.35                0.04                    48                0.96 (0.85,1.08)   0.75   0.45   11
  CC vs TT                       16.28                0.02                    57                1.06 (0.83,1.35)   0.47   0.64   11
  CT + CC vs TT                  13.67                0.09                    41                1.06 (0.96,1.16)   1.17   0.24   11
  CC vs CT + TT                  5.98                 0.54                    0                 1.18 (1.06,1.31)   3.14   0.00   12
  Source of control Population                                                                                                   
  C vs T                         78.91                \< 0.01                 60                0.92 (0.83,1.02)   1.53   0.13   17
  CT vs TT                       20.50                0.20                    22                0.95 (0.88,1.01)   1.59   0.11   17
  CC vs TT                       29.47                0.02                    46                1.00 (0.86,1.16)   0.04   0.97   17
  CT + CC vs TT                  26.00                0.05                    38                0.96 (0.90,1.03)   1.06   0.29   17
  CC vs CT + TT                  27.06                0.06                    38                1.01 (0.94,1.10)   0.32   0.75   18
  Hospital                                                                                                                       
  C vs T                         13.71                0.01                    65                0.97 (0.68,1.38)   0.17   0.86   3
  CT vs TT                       3.34                 0.19                    40                0.98 (0.83,1.15)   0.30   0.77   3
  CC vs TT                       17.29                \< 0.01                 68                0.83 (0.64,2.03)   0.40   0.69   3
  CT + CC vs TT                  7.75                 0.02                    64                0.99 (0.69,1.43)   0.05   0.96   3
  CC vs CT + TT                  15.24                \< 0.01                 67                0.82 (0.57,1.80)   0.49   0.62   3
  Sample size                                                                                                                    
  ≥ 300                                                                                                                          
  C vs T                         76.76                \< 0.01                 66                0.99 (0.87,1.12)   0.19   0.85   12
  CT vs TT                       12.83                0.30                    14                0.99 (0.92,1.06)   0.34   0.74   12
  CC vs TT                       35.37                \< 0.01                 59                1.04 (0.86,1.26)   0.42   0.68   12
  CT + CC vs TT                  21.90                0.03                    50                1.00 (0.91,1.10)   0.04   0.97   12
  CC vs CT + TT                  30.33                \< 0.01                 64                1.03 (0.90,1.19)   0.47   0.64   13
  \< 300                                                                                                                         
  C vs T                         7.50                 0.38                    7                 0.92 (0.94,1.11)   1.88   0.06   8
  CT vs TT                       4.34                 0.74                    0                 0.89 (0.78,1.02)   1.74   0.08   8
  CC vs TT                       12.99                0.07                    46                0.82 (0.65,1.04)   1.66   0.10   8
  CT + CC vs TT                  5.03                 0.66                    0                 0.90 (0.80,1.03)   1.70   0.09   8
  CC vs CT + TT                  13.13                0.07                    47                0.93 (0.75,1.14)   0.73   0.47   8

For the rs895819 polymorphism, we failed to find any associations between rs895819 polymorphism and cancer risk (Table [3](#T3){ref-type="table"}, Figure [4](#F4){ref-type="fig"}). In the subgroup analysis by ethnicity, statistically significantly reduced cancer risks were found among Asian for dominant contrast (AG + GG vs AA: OR = 1.24, 95% CI: 1.03--1.50, *P* = 0.02) (Table [5](#T5){ref-type="table"}). In contrast, a subtly decreased risk was observed in the Caucasian population (G vs A: OR = 0.92, 95% CI: 0.85--0.99, *P* = 0.03; AG vs AA: OR = 0.92, 95% CI: 0.85--0.99, *P* = 0.00) (Table [5](#T5){ref-type="table"}). Subgroup analysis by cancer types revealed a decreased risk in breast cancer (G vs A: OR = 0.92, 95% CI: 0.86--0.99, *P* = 0.03; AG vs AA: OR = 0.83, 95% CI: 0.75--0.92, *P* \< 0.01; AG + GG vs AA: OR = 0.88, 95% CI: 0.80--0.97, *P* = 0.01), whereas a significantly increased risk was observed in colorectal cancer (GG vs AA: OR = 1.45, 95% CI: 1.10--1.92, *P* \< 0.01; AG + GG vs AA: OR = 1.35, 95% CI: 1.15--1.58, *P* \< 0.01; GG vs AG + AA: OR = 1.36, 95% CI: 1.04--1.77, *P* = 0.02) (Table [5](#T5){ref-type="table"}).

![Forest plot of cancer risk associated with rs895819 for the GG vs AA compared with the AA genotype](oncotarget-07-22368-g004){#F4}

###### Stratified analyses of the rs895819 polymorphism on cancer risk

  Comparisons                    Heterogeneity test   Summary OR (*95% CI*)   Hypothesis test   Studies                           
  ------------------------------ -------------------- ----------------------- ----------------- ------------------- ------ ------ ----
  Ethnic                                                                                                                          
  Asian                                                                                                                           
  G vs A                         34.11                \< 0.01                 68                1.02 (0.91,1.14)    0.27   0.79   12
  AG vs AA                       27.19                0.01                    60                1.09 (0.95,1.26)    1.25   0.21   12
  GG vs AA                       24.68                0.01                    55                1.09 (0.87,1.37)    0.73   0.47   12
  AG + GG vs AA                  53.69                \< 0.01                 80                1.24 (1.03,1.50)    2.28   0.02   12
  GG vs AG + AA                  30.73                \< 0.01                 64                1.03 (0.81,1.31)    0.25   0.80   12
  Caucasian                                                                                                                       
  G vs A                         6.91                 0.33                    13                0.92 (0.86,0.99)    2.27   0.02   7
  AG vs AA                       7.70                 0.26                    22                0.81 (0.73,0.89)    3.82   0.00   7
  GG vs AA                       6.74                 0.35                    11                0.95 (0.80,1.12)    0.65   0.51   7
  AG + GG vs AA                  4.17                 0.65                    0                 0.87 (0.79,0.95)    2.69   0.00   7
  GG vs AG + AA                  6.47                 0.37                    7                 1.03 (0.88,1.02)    0.34   0.74   7
  Breast cancer                                                                                                                   
  G vs A                         8.76                 0.12                    43                0.92 (0.86,0.99)    2.15   0.03   6
  AG vs AA                       11.41                0.04                    56                0.83 (0.75,0.92)    3.51   0.00   6
  GG vs AA                       1.17                 0.95                    0                 0.90 (0.76,1.07)    1.21   0.23   6
  AG + GG vs AA                  5.80                 0.33                    14                0.88 (0.80,0.97)    2.58   0.01   6
  GG vs AG + AA                  2.40                 0.79                    0                 0.98 (0.84,1.15)    0.24   0.81   6
  Gastric cancer                                                                                                                  
  G vs A                         16.96                0.00                    62                1.11 (0.84,1.46)    0.70   0.48   4
  AG vs AA                       10.15                0.02                    50                1.08 (0.80,1.47)    0.50   0.42   4
  GG vs AA                       15.44                0.00                    60                1.05 (0.55,1.99)    0.15   0.88   4
  AG + GG vs AA                  13.52                0.00                    58                1.10 (0.79,1.53)    0.55   0.58   4
  GG vs AG + AA                  12.52                0.01                    56                1.02 (0.59,1.76)    0.07   0.94   4
  Colorectal Cancer                                                                                                               
  G vs A                         1.78                 0.62                    0                 1.07 (0.94,1.21)    1.06   0.29   4
  AG vs AA                       3.42                 0.33                    12                1.14 (0.96,1.35)    1.47   0.14   4
  GG vs AA                       3.40                 0.33                    12                1.45 (1.10,1.92)    2.66   0.00   4
  AG + GG vs AA                  7.81                 0.05                    62                1.35 (1.15,1.58)    3.65   0.00   4
  GG vs AG + AA                  2.52                 0.47                    0                 1.36 (1.04,1.77)    2.27   0.02   4
  Other cancers                                                                                                                   
  G vs A                         2.12                 0.55                    0                 0.87 (0.79,0.96)    2.87   0.00   4
  AG vs AA                       7.08                 0.07                    58                0.92 (0.81,1.04)    1.30   0.19   4
  GG vs AA                       2.49                 0.48                    0                 0.96 (0.76,1.22)    0.30   0.77   4
  AG + GG vs AA                  22.87                0.00                    70                1.26 (0.77,2.07)    0.92   0.36   4
  GG vs AG + AA                  1.70                 0.64                    0                 1.05 (0.84,1.33)    0.45   0.65   4
  Source of control Population                                                                                                    
  G vs A                         28.89                0.01                    58                0.99 (0.90,1.10)    0.18   0.86   13
  AG vs AA                       43.20                0.00                    72                1.02 (0.86,1.21)    0.22   0.83   13
  GG vs AA                       14.44                0.27                    17                1.06 (0.93,1.21)    0.83   0.41   13
  AG + GG vs AA                  61.57                0.00                    81                1.14 (0.94,1.38)    1.36   0.17   13
  GG vs AG + AA                  20.53                0.06                    42                1.03 (0.91,1.17)    0.46   0.65   13
  Hospital                                                                                                                        
  G vs A                         14.18                0.01                    65                0.99 (0.86,1.15)    0.08   0.94   6
  AG vs AA                       7.78                 0.17                    36                0.94 (0.84,1. 05)   1.11   0.27   6
  GG vs AA                       18.75                0.00                    73                0.98 (0.65,1.49)    0.08   0.94   6
  AG + GG vs AA                  27.21                0.00                    82                1.10 (0.84,1.43)    0.68   0.50   6
  GG vs AG + AA                  16.68                0.01                    70                1.06 (0.73,1.55)    0.32   0.75   6
  Sample size                                                                                                                     
  ≥ 300                                                                                                                           
  G vs A                         22.21                0.02                    59                0.95 (0.87,1.04)    1.16   0.25   10
  AG vs AA                       27.95                0.01                    68                0.92 (0.80,1.05)    1.23   0.22   10
  GG vs AA                       21.34                0.01                    58                0.99 (0.80,1.23)    0.05   0.96   10
  AG + GG vs AA                  76.99                0.00                    88                1.09 (0.88,1.35)    0.77   0.44   10
  GG vs AG + AA                  17.22                0.05                    48                1.03 (0.91,1.16)    0.42   0.67   10
  \< 300                                                                                                                          
  G vs A                         13.95                0.08                    43                1.08 (0.98,1.18)    1.45   0.15   9
  AG vs AA                       12.81                0.12                    38                1.15 (1.00,1.33)    2.02   0.04   9
  GG vs AA                       8.96                 0.35                    11                1.22 (0.99,1.50)    1.85   0.06   9
  AG + GG vs AA                  9.82                 0.28                    19                1.19 (0.98,1.32)    1.74   0.07   9
  GG vs AG + AA                  19.99                0.01                    60                1.08 (0.77,1.50)    0.44   0.66   9

Test of heterogeneity {#s2_4}
---------------------

In the overall pooled analysis, the results showed that both rs2292832 and rs895819 had heterogeneity in part of genotype with *P* value less than 0.05. Therefore, we analyzed the summary ORs with random-effect models if the heterogeneity existed. Fixed-effect models were used to analyze the summary odds ratios for the rest. Subsequently, meta regression in Stata12.0 was used to assess the source of heterogeneity for rs2292832 and rs895819, including publication year, ethnicity (Asians, Caucasians), cancer type, matched controls (yes or not), language (English or Chinese), source of control (hospital or population), assay, sample size (300 as the boundary) and quality control (with or without). It was detected that the systemic results were not altered by these characteristics (Table [6](#T6){ref-type="table"}).

###### The results of heterogeneity test for rs2292832 and rs895819

  Comparisons     Publication year   Ethnicity   Cancer type   Match   Language   Source of control   Assay   Sample size   Quality control
  --------------- ------------------ ----------- ------------- ------- ---------- ------------------- ------- ------------- -----------------
  rs2292832                                                                                                                 
  C vs T          0.737              0.339       0.256         0.812   0.653      0.547               0.417   0.291         0.781
  CT vs TT        0.392              0.440       0.331         0.329   0.220      0.514               0.519   0.765         0.529
  CC vs TT        0.388              0.838       0.463         0.784   0.463      0.875               0.772   0.573         0.514
  CT + CC vs TT   0.737              0.440       0.547         0.956   0.853      0.443               0.949   0.552         0.554
  CC vs CT + TT   0.519              0.519       0.440         0.331   0.389      0.396               0.838   0.336         0.815
  rs895819                                                                                                                  
  G vs A          0.418              0.426       0.275         0.581   0.593      0.581               0.336   0.581         0.225
  AG vs AA        0.440              0.841       0.415         0.797   0.596      0.797               0.554   0.797         0.442
  GG vs AA        0.838              0.721       0.487         0.998   0.827      0.498               0.423   0.998         0.366
  AG + GG vs AA   0.418              0.426       0.159         0.989   0.656      0.989               0.359   0.989         0.396
  GG vs AG + AA   0.327              0.841       0.881         0.077   0.914      0.077               0.073   0.077         0.990

Evaluation of publication bias {#s2_5}
------------------------------

Begg\'s funnel plot and Egger\'s test (Table [7](#T7){ref-type="table"}) were performed to assess the publication bias of the currently available literature. The shape of the funnel plots did not reveal any evidence of obvious asymmetry in all comparison models (Figure [5](#F5){ref-type="fig"} and Figure [6](#F6){ref-type="fig"}).

###### Publication bias of rs2292832 and rs895819 for Egger\'s test

  Comparisons     *t*     *p*     *95% CI*
  --------------- ------- ------- --------------
  rs2292832                       
  T vs C          0.96    0.358   −1.657∼4.245
  CT vs CC        −0.45   0.661   −1.748∼1.151
  TT vs CC        0.96    0.358   −1.171∼3.001
  CT + TT vs CC   0.37    0.715   −1.256∼1.777
  TT vs CT + CC   1.60    0.083   −0.572∼3.100
  rs895819                        
  G vs A          0.44    0.673   −2.337∼3.452
  AG vs AA        1.18    0.270   −1.122∼3.555
  GG vs AA        0.28    0.789   −1.792∼2.291
  AG + GG vs AA   1.12    0.292   −1.219∼3.612
  GG vs AG + AA   −0.07   0.943   −1.923∼1.803

![Funnel plot of rs2292832 polymorphism and cancer risk for dominant models (TT + CT vs CC)\
The horizontal line in the funnel plot indicates the fixed-effects summary estimate, whereas the sloping lines indicate the expected 95% CI for a given SE.](oncotarget-07-22368-g005){#F5}

![Funnel plot of rs895819 polymorphism and cancer risk for dominant models (TT + CT vs CC)](oncotarget-07-22368-g006){#F6}

Sensitivity analysis {#s2_6}
--------------------

A single study included in the meta-analysis was deleted each time to reflect the influence of the individual data set to the pooled ORs, and the corresponding pooled ORs were not materially changed (data not shown).

DISCUSSION {#s3}
==========

In the present study, an association between the two common SNPs in microRNAs (rs2292832 and rs895819) and cancer risk was evaluated by the pooled results from 40 published studies. The results demonstrated that the rs2292832 was associated with a significantly reduced risk for developing cancer in the breast cancer (dominant and recessive model), and for the rs895819 G allele, AG genotype and dominant model were associated with a decreased risk for Caucasian population and breast cancer, in contrast, a subtly increased risk was observed in a Asian population (dominant model) and colorectal cancer (GG genotype, dominant model and recessive model).

Thus far, for the rs2292832, no significant association was observed in overall pooled results \[[@R54], [@R55]\]. In contrast to the published results, this study revealed the different association between rs2292832 polymorphism and breast cancer risk. This suggests that the molecular mechanisms underlying the genetic associations of miRNA-SNPs with cancer are complex and vary by cancer site. Considering the influence of the T allele in rs2292832 might be masked by the presence of other as-yet unidentified causal genes involved in cancer development on this polymorphism \[[@R56]\], our results should be interpreted with caution, and more studies will need to be analyzed to confirm the results.

The rs895819 is well recognized to be involved in the pathogenesis, metastasis, and invasion of multiple cancer types, by functioning as an oncogene via complex mechanisms \[[@R57]--[@R59]\]. The rs895819, as an oncomiR, exhibited its oncogenic activity through regulating target genes \[[@R60], [@R61]\]. It means that down-regulation of miR-27a may contribute to decreased cancer risk through up-regulating the targets. Although the binding of the mature miRNA to target mRNAs was not influenced by the rs895819 \[[@R62]\], some published studies had demonstrated that polymorphisms in premiRNAs could influence the expression of their mature forms, as well as were involved in the binding of some nuclear factors in miRNA processing \[[@R63]\]. Therefore, we presumed that rs895819 affected the processing or/and expression of miR-27a, which resulted in down-regulation of miR-27a. The presumption was supported by our findings in breast cancer subgroup.

This comprehensive and updated meta-analysis further support the rs895819 G allele was associated with a decreased risk for breast cancer, whereas a subtly increased risk was observed in colorectal cancer. In addition, significant associations with an increased risk for the Caucasian population, but a significantly reduced risk for the Asian population, suggesting a possible ethnic difference in the genetic background and the environment, which was the similar to that reported by Wang et al. \[[@R64]\] and Zhong et al. \[[@R65]\]. However, the risk of different cancer types and multiethnic should be confirmed by more studies.

Although meta-analysis is robust, our study still has some limitations. Firstly, we pooled the data based on unadjusted information and lack the consideration of combination genetic factors together with environmental exposures, while a more precise analysis needs to be conducted if individual data are available. Secondly, although all eligible studies were summarized, the relatively small sample size of studies may lead to reduced statistical power when stratified according to the cancer type or ethnicity. Thirdly, the different genotyping strategies may contribute to the bias in the analysis. Fourthly, Publication bias may exist, because only published studies were included in this meta-analysis, although the result for publication bias was not statistically significant. Finally, the data sets without excluding the studies with inefficient scores base on NOS.

In summary, current data suggest that the rs2292832 polymorphism may contribute to increased susceptibility to breast cancer, and the rs895819 polymorphism was a protective factor for cancer development among Caucasian and may contribute to breast and colorectal cancer susceptibility. Further multi-centric studies are still needed to confirm the present results.

MATERIALS AND METHODS {#s4}
=====================

Identification of eligible studies {#s4_1}
----------------------------------

A comprehensive literature search was conducted using the PubMed, Springer, Elsevier, CNKI (Chinese), and Wanfang (Chinese) Digital Dissertations Databases for relevant articles published in English or Chinese up to July 2015 with key words 'microRNA/miR-149/miR-27a', 'rs2292832/rs895819','polymorphism', and 'cancer'. The full text of the candidate articles were examined carefully to determine whether they accorded with the inclusion criteria for the meta-analysis. The present study was conducted in accordance with PRISMA guidelines \[[@R66]\].

The inclusion criteria were as follows: 1) about the rs2292832/rs895819 polymorphisms and cancer risk, 2) based on case-control studies (including cohort studies), 3) sufficient published data for estimating an odds ratio (OR) with 95% confidence interval (CI), and 4) genotype distribution of control groups must be in accordance with the assumptions of Hardy-Weinberg equilibrium (HWE).

In case of redundant publications, only the studies with the largest sample size and/or latest published date were included.

Data extraction {#s4_2}
---------------

Data were extracted independently by two investigators (YJF and FJD). Data for analyses, including first author, publication year, cancer type, country of origin, ethnicity, study design, genotype detection methods and quality control or not. If discrepancies existed, consensus would be finally reached on discussion.

Quality assessment {#s4_3}
------------------

Quality assessment criteria were utilized to evaluate methodological quality of included studies based on Newcastle-Ottawa Scale (NOS) \[[@R67]\] for quality of case-control. A nine-point scale of the NOS (range, 0--9 points) has been developed for the evaluation, a high-quality study was defined as one with a score of ≥ 7.

Statistical analysis {#s4_4}
--------------------

The analyses were conducted in Review Manager 5.0 (Version 5 for Windows, Cochrane Collaboration, Oxford, UK). The overall strength of an association between rs2292832 and rs895819 polymorphisms and cancer risk assessed by crude ORs together with their corresponding 95% CIs. The stratified analysis was conducted by ethnicity (Asians, Caucasians), cancer type, source of control and sample size (300 as the boundary).

Heterogeneity in meta-analysis refers to the variation in study outcomes between different studies. Between-study heterogeneity was evaluated with a χ^*2*^ based *Q*-test among the studies \[[@R68]\]. Heterogeneity was considered significant when *P \< 0.05*. In case of no significant heterogeneity, point estimates and 95% CI was estimated using the fixed effect model (Mantel-Haenszel), otherwise, random effects model (DerSimonian Laird) was employed \[[@R69], [@R70]\]. The significance of overall OR was determined by the *Z*-test.

If there were significant heterogeneity among included studies, the sources of heterogeneity would be explored using meta-regression in Stata 12.0 (StataCorp, College Station, TX, USA). To assess the stability of the results, one-way sensitivity analyses were performed to assess the stability of the results, in which a single study in the meta-analysis was deleted each time to reflect the influence of the individual data set to the pooled OR. The publication bias was diagnosed by using inverted funnel plots, Begg\'s test and the Egger\'s test by Stata 12.0. Statistical tests performed in the present analysis were considered significant whenever the corresponding null-hypothesis probability was *P* \< 0.05.
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